| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC1787 | Diflorasone | Corticosteroid Hormone Receptor Agonist |
|
| DCC1788 | Dihydralazine | Novel dose-dependent inhibitor of the SARS-CoV-2 Mac1 Macrodomain |
|
| DCC1789 | Dihydrexidine Hydrochloride | D1-like full agonist with similar affinity for D1 and D5, and roughly 10-fold selectivity over D2-like receptors |
|
| DCC1790 | dihydro-beta-erythroidine Hydrobromide | Competitive nicotinic receptor antagonist |
|
| DCC1791 | Dihydrocyclosporin A | Closely related co-metabolite of cyclosporin A |
|
| DCC1792 | Dihydromotuporamine C Trihydrochloride | Unique antimigration and antiangiogenic agent |
|
| DCC1793 | Diic16tac | Novel lipid-based, high-density, environmentally sensitive (HIDE) probe |
|
| DCC1794 | Diic16'tco | Novel lipid-based, high-density, environmentally sensitive (HIDE) probe |
|
| DCC1795 | Dilazep | Vasodilator for the treatment of cardiopathy and renal disorders, acting as an adenosine reuptake inhibitor. |
|
| DCC1796 | Dimenthyl (1s,2s)-cyclopropane-1,2-dicarboxylate | Building Block |
|
| DCC1797 | Dimenthyl Succinate | Building Block |
|
| DCC1798 | dimethacrine | Novel inhibitor of AMA1-RON2 interaction, blocking merozoite invasion from schizont-infected RBCs; Antidepressant; Acetylcholinesterase inhibitor |
|
| DCC1799 | Dimethothiazine | Serotonin antagonist and histamine antagonist |
|
| DCC1800 | Dimethoxy-etomidate | Novel analog of etomidate, potently inhibiting 11-beta-hydroxylase without GABAA receptor positive modulatory and sedative-hypnotic activities |
|
| DCC1801 | Diminazene | Anti-infective agent against certain protozoa such as Babesia, Trypanosoma, Cytauxzoon, and certain bacteria including Brucella and Streptococcus |
|
| DCC1802 | Dimiq Hydrochloride | Inhibitor of Topoisomerase>DNA topoisomerase II; very potent cytotoxic antitumor agent |
|
| DCC1803 | Dinalbuphine Sebacate | Long-lasting prodrug of nalbuphine, acting as a moderate-efficacy partial agonist or antagonist of the μ-opioid receptor and as a high-efficacy partial agonist of the κ-opioid receptor |
|
| DCC1804 | Dinapsoline | Natural full D1 dopamine receptor agonist |
|
| DCC1805 | Dipicrylamine Sodium Salt | Potent antagonist of GABA A receptors that contain alpha1 and beta2 subunits |
|
| DCC1806 | Dipquo | Novel activator of the bone marker alkaline phosphatase (ALP), markedly promoting osteoblast differentiation, including expression of Runx2, Osterix, and Osteocalcin, mediating osteogenesis through activation of p38-β |
|
| DCC1807 | Dipraglurant | Novel negative allosteric modulator of the mGlu5 receptor |
|
| DCC1808 | Displurigen | Inhibitor of ATPase activity of HSP70 |
|
| DCC1809 | Distamycin A Hydrochloride | Antibiotic, specifically inhibiting the initiation of RNA synthesis, binding isohelically to the minor groove of B-DNA at A/T rich sites |
|
| DCC1810 | Distigmine Dibromide | Parasympathomimetic with longer duration of action |
|
| DCC1811 | Djt06001 | Novel selective Factor Xa inhibitor, reducing thrombus formation with low risk of bleeding |
|
| DCC1812 | Dk-1-150 | Novel inducer of apoptotic cell death in TNBC cell lines without causing cytotoxicity in the normal mammary epithelial cell line |
|
| DCC1813 | Dk-1-166 | Novel inducer of apoptotic cell death in TNBC cell lines without causing cytotoxicity in the normal mammary epithelial cell line |
|
| DCC1814 | Dk-139 | Inhibitor of NF-kappaB-mediated GROalpha expression, suppressing the TNFalpha-induced invasive capability of MDA-MB-231 human breast cancer cells |
|
| DCC1815 | Dk-1-49 | Novel autophagonizer, inducing autophagic cell death in apoptosis-defective cell line |
|
| DCC1816 | Dl0410 | Novel acetylcholinesterase inhibitor, promoting synaptic function and neuronal survival, ameliorating cognitive deficits in SAMP8 mice via improved mitochondrial dynamics and increased activity of the NMDAR-CREB-BDNF pathway |
|
